Pleural effusions in patients with chronic myeloid leukaemia treated with dasatinib may have an immune-mediated pathogenesis.
de Lavallade
Hugues
H
Punnialingam
Sinthiya
S
Milojkovic
Dragana
D
Bua
Marco
M
Khorashad
Jamshid S
JS
Gabriel
Ian H
IH
Chaidos
Aristeidis
A
Olavarria
Eduardo
E
Goldman
John M
JM
Apperley
Jane F
JF
Marin
David
D
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects*; D001327:Autoimmune Diseases / Q000139:chemically induced; D000069439:Dasatinib; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D008875:Middle Aged; D016066:Pleural Effusion, Malignant / Q000139:chemically induced*; D011743:Pyrimidines / Q000009:adverse effects*; D012189:Retrospective Studies; D013844:Thiazoles / Q000009:adverse effects*
D000970:Antineoplastic Agents; D011743:Pyrimidines; D013844:Thiazoles; D000069439:Dasatinib